• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
PopulationGenerally healthy postmenopausal women eligible for menopausal hormone therapy. Characteristics of enrolled participants are applicable to the U.S. primary care population.Animals, men, premenopausal women, postmenopausal women with contraindications for hormone therapy use, or populations not applicable to U.S. primary care.
InterventionsEstrogen only or combined with progestin for prevention of chronic conditions. Medications are available for use in the United States.Contraceptives, other hormones, or treatment of menopausal symptoms.
OutcomesHealth outcomes include mortality, fractures; coronary heart disease; stroke; venous thromboembolism; breast, colorectal, endometrial, and ovarian cancer; cholecystitis; cognition; urinary incontinence; and others.Menopausal symptoms; intermediate health outcomes, such as lipid levels or bone mineral density.
Study types and designsEnglish-language randomized, controlled trials published in 2002 or later.Observational studies (case-control and cohort) or case studies.
Duration1 year of treatment.Less than 1 year of treatment.

From: Appendix B, Detailed Methods

Cover of Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations.
Evidence Syntheses, No. 93.
Nelson HD, Walker M, Zakher B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.